For the study, researchers conducted an observation trial of oncology patients with a central venous catheter. They compared outcomes for patients with alcohol-impregnated port protectors and needless neutral pressure connector to those received regular care.
After the trial period was over, researchers found patients with the intervention saw one CLABSI over 3,005 central line-days, compared to 16 CLABSIs over 6,851 central line-days for control patients. In addition, intervention patients saw a 0.2 percent rate of contaminated blood cultures, compared to 2.5 percent contamination rate for control patients.
Related Articles on CLABSI:
UC Davis CMO Dr. Allan Siefkin: Creating a Culture of Safety, Quality
10 Statistics on Central Line-Associated Bloodstream Infections in the U.S.
CMS Releases FY 2013 IPPS Proposed Rule: 12 Points to Know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
